Dapagliflozin Improved Cardiac Function and Structure in Diabetic Patients with Preserved Ejection Fraction: Results of a Single Centre, Observational Prospective Study
Sodium-glucose cotransporter inhibitors (SGLT2i) have demonstrated a reduction in cardiovascular events in diabetes and heart failure (HF). The mechanisms underlying this benefit are not well known and data are contradictory. The purpose of this study is to analyse the effect of dapagliflozin on car...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/20/6698 |
| _version_ | 1797573437888135168 |
|---|---|
| author | Marcelino Cortés Oscar Lorenzo Jairo Lumpuy-Castillo Sacramento Martínez-Albaladejo Mikel Taibo-Urquía Ana María Pello Antonio José Bollas Miguel Orejas Miguel Ángel Navas Ester Macia María Esther Martínez Andrea Rueda Jose Tuñón |
| author_facet | Marcelino Cortés Oscar Lorenzo Jairo Lumpuy-Castillo Sacramento Martínez-Albaladejo Mikel Taibo-Urquía Ana María Pello Antonio José Bollas Miguel Orejas Miguel Ángel Navas Ester Macia María Esther Martínez Andrea Rueda Jose Tuñón |
| author_sort | Marcelino Cortés |
| collection | DOAJ |
| description | Sodium-glucose cotransporter inhibitors (SGLT2i) have demonstrated a reduction in cardiovascular events in diabetes and heart failure (HF). The mechanisms underlying this benefit are not well known and data are contradictory. The purpose of this study is to analyse the effect of dapagliflozin on cardiac structure and function in patients with normal ejection fraction. Between October 2020 and October 2021, we consecutively included 31 diabetic patients without prior history of SGLT2i use. In all of them, dapagliflozin treatment was started. At inclusion and during six months of follow-up, different clinical, ECG, analytical, and echocardiographic (standard, 3D, and speckle tracking) variables were recorded. After a follow-up period of 6.6 months, an average reduction of 18 g (<i>p</i> = 0.028) in 3D-estimated left ventricle mass was observed. An increase in absolute left ventricle global longitudinal strain (LV-GLS) of 0.3 (<i>p</i> = 0.036) was observed, as well as an increase in isovolumetric relaxation time (IVRT) of 10.5 ms (<i>p</i> = 0.05). Moreover, dapagliflozin decreased the levels of plasma creatin-kinase (CK-MB) and atrial natriuretic peptide (ANP). In conclusion, our data show that the use of SGLT2i is associated with both structural (myocardial mass) and functional (IVRT, LV-GLS) cardiac improvements in a population of diabetic patients with normal ejection fraction. |
| first_indexed | 2024-03-10T21:09:32Z |
| format | Article |
| id | doaj.art-1150a849db944beab8327784c90995ed |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T21:09:32Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-1150a849db944beab8327784c90995ed2023-11-19T16:54:46ZengMDPI AGJournal of Clinical Medicine2077-03832023-10-011220669810.3390/jcm12206698Dapagliflozin Improved Cardiac Function and Structure in Diabetic Patients with Preserved Ejection Fraction: Results of a Single Centre, Observational Prospective StudyMarcelino Cortés0Oscar Lorenzo1Jairo Lumpuy-Castillo2Sacramento Martínez-Albaladejo3Mikel Taibo-Urquía4Ana María Pello5Antonio José Bollas6Miguel Orejas7Miguel Ángel Navas8Ester Macia9María Esther Martínez10Andrea Rueda11Jose Tuñón12Cardiology Department, Fundación Jiménez Díaz Hospital, 28040 Madrid, SpainLaboratory of Diabetes and Vascular Pathology, IIS-Fundación Jiménez Díaz, Universidad Autónoma, 28040 Madrid, SpainLaboratory of Diabetes and Vascular Pathology, IIS-Fundación Jiménez Díaz, Universidad Autónoma, 28040 Madrid, SpainLaboratory of Diabetes and Vascular Pathology, IIS-Fundación Jiménez Díaz, Universidad Autónoma, 28040 Madrid, SpainCardiology Department, Fundación Jiménez Díaz Hospital, 28040 Madrid, SpainCardiology Department, Fundación Jiménez Díaz Hospital, 28040 Madrid, SpainCardiology Department, Fundación Jiménez Díaz Hospital, 28040 Madrid, SpainCardiology Department, Fundación Jiménez Díaz Hospital, 28040 Madrid, SpainCardiology Department, Fundación Jiménez Díaz Hospital, 28040 Madrid, SpainCardiology Department, Fundación Jiménez Díaz Hospital, 28040 Madrid, SpainCardiology Department, Fundación Jiménez Díaz Hospital, 28040 Madrid, SpainCardiology Department, Fundación Jiménez Díaz Hospital, 28040 Madrid, SpainCardiology Department, Fundación Jiménez Díaz Hospital, 28040 Madrid, SpainSodium-glucose cotransporter inhibitors (SGLT2i) have demonstrated a reduction in cardiovascular events in diabetes and heart failure (HF). The mechanisms underlying this benefit are not well known and data are contradictory. The purpose of this study is to analyse the effect of dapagliflozin on cardiac structure and function in patients with normal ejection fraction. Between October 2020 and October 2021, we consecutively included 31 diabetic patients without prior history of SGLT2i use. In all of them, dapagliflozin treatment was started. At inclusion and during six months of follow-up, different clinical, ECG, analytical, and echocardiographic (standard, 3D, and speckle tracking) variables were recorded. After a follow-up period of 6.6 months, an average reduction of 18 g (<i>p</i> = 0.028) in 3D-estimated left ventricle mass was observed. An increase in absolute left ventricle global longitudinal strain (LV-GLS) of 0.3 (<i>p</i> = 0.036) was observed, as well as an increase in isovolumetric relaxation time (IVRT) of 10.5 ms (<i>p</i> = 0.05). Moreover, dapagliflozin decreased the levels of plasma creatin-kinase (CK-MB) and atrial natriuretic peptide (ANP). In conclusion, our data show that the use of SGLT2i is associated with both structural (myocardial mass) and functional (IVRT, LV-GLS) cardiac improvements in a population of diabetic patients with normal ejection fraction.https://www.mdpi.com/2077-0383/12/20/6698sodium-glucose cotransporter type 2 inhibitorsdapagliflozinspeckle trackingbiomarkersechocardiography |
| spellingShingle | Marcelino Cortés Oscar Lorenzo Jairo Lumpuy-Castillo Sacramento Martínez-Albaladejo Mikel Taibo-Urquía Ana María Pello Antonio José Bollas Miguel Orejas Miguel Ángel Navas Ester Macia María Esther Martínez Andrea Rueda Jose Tuñón Dapagliflozin Improved Cardiac Function and Structure in Diabetic Patients with Preserved Ejection Fraction: Results of a Single Centre, Observational Prospective Study Journal of Clinical Medicine sodium-glucose cotransporter type 2 inhibitors dapagliflozin speckle tracking biomarkers echocardiography |
| title | Dapagliflozin Improved Cardiac Function and Structure in Diabetic Patients with Preserved Ejection Fraction: Results of a Single Centre, Observational Prospective Study |
| title_full | Dapagliflozin Improved Cardiac Function and Structure in Diabetic Patients with Preserved Ejection Fraction: Results of a Single Centre, Observational Prospective Study |
| title_fullStr | Dapagliflozin Improved Cardiac Function and Structure in Diabetic Patients with Preserved Ejection Fraction: Results of a Single Centre, Observational Prospective Study |
| title_full_unstemmed | Dapagliflozin Improved Cardiac Function and Structure in Diabetic Patients with Preserved Ejection Fraction: Results of a Single Centre, Observational Prospective Study |
| title_short | Dapagliflozin Improved Cardiac Function and Structure in Diabetic Patients with Preserved Ejection Fraction: Results of a Single Centre, Observational Prospective Study |
| title_sort | dapagliflozin improved cardiac function and structure in diabetic patients with preserved ejection fraction results of a single centre observational prospective study |
| topic | sodium-glucose cotransporter type 2 inhibitors dapagliflozin speckle tracking biomarkers echocardiography |
| url | https://www.mdpi.com/2077-0383/12/20/6698 |
| work_keys_str_mv | AT marcelinocortes dapagliflozinimprovedcardiacfunctionandstructureindiabeticpatientswithpreservedejectionfractionresultsofasinglecentreobservationalprospectivestudy AT oscarlorenzo dapagliflozinimprovedcardiacfunctionandstructureindiabeticpatientswithpreservedejectionfractionresultsofasinglecentreobservationalprospectivestudy AT jairolumpuycastillo dapagliflozinimprovedcardiacfunctionandstructureindiabeticpatientswithpreservedejectionfractionresultsofasinglecentreobservationalprospectivestudy AT sacramentomartinezalbaladejo dapagliflozinimprovedcardiacfunctionandstructureindiabeticpatientswithpreservedejectionfractionresultsofasinglecentreobservationalprospectivestudy AT mikeltaibourquia dapagliflozinimprovedcardiacfunctionandstructureindiabeticpatientswithpreservedejectionfractionresultsofasinglecentreobservationalprospectivestudy AT anamariapello dapagliflozinimprovedcardiacfunctionandstructureindiabeticpatientswithpreservedejectionfractionresultsofasinglecentreobservationalprospectivestudy AT antoniojosebollas dapagliflozinimprovedcardiacfunctionandstructureindiabeticpatientswithpreservedejectionfractionresultsofasinglecentreobservationalprospectivestudy AT miguelorejas dapagliflozinimprovedcardiacfunctionandstructureindiabeticpatientswithpreservedejectionfractionresultsofasinglecentreobservationalprospectivestudy AT miguelangelnavas dapagliflozinimprovedcardiacfunctionandstructureindiabeticpatientswithpreservedejectionfractionresultsofasinglecentreobservationalprospectivestudy AT estermacia dapagliflozinimprovedcardiacfunctionandstructureindiabeticpatientswithpreservedejectionfractionresultsofasinglecentreobservationalprospectivestudy AT mariaesthermartinez dapagliflozinimprovedcardiacfunctionandstructureindiabeticpatientswithpreservedejectionfractionresultsofasinglecentreobservationalprospectivestudy AT andrearueda dapagliflozinimprovedcardiacfunctionandstructureindiabeticpatientswithpreservedejectionfractionresultsofasinglecentreobservationalprospectivestudy AT josetunon dapagliflozinimprovedcardiacfunctionandstructureindiabeticpatientswithpreservedejectionfractionresultsofasinglecentreobservationalprospectivestudy |